ENTA · Enanta Pharmaceuticals Inc
$13.16
-0.28 (-2.08%)
At close · Aug 14
Market Cap
$383.29M
Shares
29.13M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$13.16
Open$13.38
Day$12.96–13.40
52W close$7.17–16.85
Avg vol 30d168K
Short int2.6M · 8.9% float · 17.7d
Short vol61%
Last earningsNov 25, 2024
DataJan 2020–Aug 2026
Filing10-Q · Aug 12
Up next
FQ4-26 quarter ends
~Sep 30, 2026
Est
filed Aug 12, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Buy
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−2%
below
Price vs 50-day avg
+0%
above
RSI (14)
48
neutral
MACD trend
Positive
52-week position
62%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−4%
trailing
6-month return
−2%
trailing
YTD return
−17%
this year
Relative strength
−16%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $13 › 200d $13 — 200d above 50d
Institutional flow
Distributing
-8% holders QoQ · +14 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
8.88% of float · ▲ +6.0% MoM · 17.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
122 holders — mid 3-yr range
Squeeze score
62
elevated · 0–100
Fundamentals
Revenue growth
+16%
Y/Y
EPS growth
+30%
Y/Y
Free cash flow
$-32.2M
Balance sheet
$30.3M
net cash
Quant / Vol
risk profile
Volatility
108%
annualized · 1-yr
Max drawdown
−34%
past year
ATR
4.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Prior guidance
period ended
· from the Earnings Call filed Mar 31, 2024
Research and development expense
· fiscal year 2024
$125M – $145M
General and administrative expense
· fiscal year 2024
$50M – $60M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−2%
Neutral
Price vs 50-day avg
+0%
Bullish
RSI (14)
48
Neutral
MACD trend
Positive
Bullish
52-week position
62%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $13 › 200d $13 — 200d above 50d
Institutional flow
Distributing
-8% holders QoQ · +14 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
8.88% of float · ▲ +6.0% MoM · 17.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
122 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $7
Now $13 · 62%
Range high $17
vs 200-day avg -2%
vs 50-day avg +0%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ENTA
this stock
Enanta Pharmaceuticals Inc
|
$383.29M | -16.6% | +16.5% | — | 8.9% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +11.6% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.1% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ENTA | -4.4% | -4.2% | -2.5% | +4.4% | -16.6% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -4.8% | -8.7% | -16.2% | +0.5% | -30.4% |
Key facts
CIK
1177648
CUSIP
29251M106
13F (30d)
140 filings
116 filers
Visit website
Investor relations